ATE506959T1 - Verwendung von il-18 inhibitoren - Google Patents

Verwendung von il-18 inhibitoren

Info

Publication number
ATE506959T1
ATE506959T1 AT01911662T AT01911662T ATE506959T1 AT E506959 T1 ATE506959 T1 AT E506959T1 AT 01911662 T AT01911662 T AT 01911662T AT 01911662 T AT01911662 T AT 01911662T AT E506959 T1 ATE506959 T1 AT E506959T1
Authority
AT
Austria
Prior art keywords
inhibitors
medicament
prevention
preparation
treatment
Prior art date
Application number
AT01911662T
Other languages
English (en)
Inventor
Yolande Chvatchko
Charles Dinarello
Christine Plater-Zyberk
DEVENTER Santer VAN
Menachem Rubinstein
Daniela Novick
Soo-Hyun Kim
Original Assignee
Merck Serono Sa
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa, Yeda Res & Dev filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE506959T1 publication Critical patent/ATE506959T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01911662T 2000-02-21 2001-02-20 Verwendung von il-18 inhibitoren ATE506959T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103597 2000-02-21
EP00103590 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
ATE506959T1 true ATE506959T1 (de) 2011-05-15

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01911662T ATE506959T1 (de) 2000-02-21 2001-02-20 Verwendung von il-18 inhibitoren

Country Status (31)

Country Link
US (1) US20030157094A1 (de)
EP (1) EP1257292B1 (de)
JP (1) JP4744763B2 (de)
KR (3) KR20020086540A (de)
CN (1) CN1322897C (de)
AT (1) ATE506959T1 (de)
AU (2) AU2001240636B8 (de)
BG (1) BG66134B1 (de)
BR (1) BR0108514A (de)
CA (2) CA2399298C (de)
CY (1) CY1111687T1 (de)
CZ (1) CZ304485B6 (de)
DE (1) DE60144514D1 (de)
DK (1) DK1257292T3 (de)
EA (1) EA005583B1 (de)
EE (1) EE05423B1 (de)
HK (1) HK1051965A1 (de)
HR (1) HRP20020652A2 (de)
HU (1) HU227752B1 (de)
IL (2) IL151388A0 (de)
ME (1) ME00546B (de)
MX (1) MXPA02008079A (de)
NO (1) NO331971B1 (de)
NZ (3) NZ520122A (de)
PL (1) PL206549B1 (de)
PT (1) PT1257292E (de)
RS (1) RS51737B (de)
SI (1) SI1257292T1 (de)
SK (1) SK288032B6 (de)
TR (2) TR200502508T2 (de)
WO (1) WO2001062285A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
EP1331943A4 (de) 2000-10-11 2005-01-26 Viron Therapeutics Inc Nukleinsäure-moleküle und polypeptide zur immunmodulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
US20030008822A1 (en) * 2001-05-16 2003-01-09 Charles Dinarello Use of IL-18 inhibitors for the treatment or prevention of sepsis
WO2003045400A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
WO2004064713A2 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
AU2004235595C1 (en) * 2003-04-30 2009-09-24 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
AU2004290413A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring IL-18
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20090004683A1 (en) 2004-06-30 2009-01-01 Atsuo Sekiyama Indicator Agent for Noninflammatory Stress Response and Use Thereof
WO2006009114A1 (ja) * 2004-07-16 2006-01-26 Atsuo Sekiyama Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
US7691611B2 (en) 2005-06-03 2010-04-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Ｉｌ−１８結合タンパク質の精製のための方法
EP1746167A1 (de) * 2005-07-20 2007-01-24 Apoxis SA Verfahren zur Identifizierung von Verbindungen, welche Entzündung inhibieren können.
BRPI0711908B8 (pt) 2006-05-25 2021-05-25 Glaxo Group Ltd anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
EP3978526A1 (de) * 2013-09-05 2022-04-06 AB2 Bio SA Il-18-bindendes protein (il-18bp) bei entzündungskrankheiten
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
JP2021527107A (ja) * 2018-06-14 2021-10-11 ユニベルシテ ドゥ ボルドー インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療
EP4371573A1 (de) 2021-07-13 2024-05-22 National University Corporation Tokai National Higher Education and Research System Medizinische zusammensetzung zur behandlung von entzündlicher darmerkrankung
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
WO1998022137A1 (en) * 1996-11-15 1998-05-28 The Kennedy Institute Of Rheumatology SUPPRESSION OF TNF α AND IL-12 IN THERAPY
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (de) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab Interleukin 18-bindende proteine
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
EA005583B1 (ru) 2005-04-28
KR20070087256A (ko) 2007-08-27
CA2399298C (en) 2014-04-15
NO20023962L (no) 2002-08-20
CA2399298A1 (en) 2001-08-30
IL151388A (en) 2009-09-01
WO2001062285A1 (en) 2001-08-30
DE60144514D1 (de) 2011-06-09
HK1051965A1 (en) 2003-08-29
HUP0300061A3 (en) 2005-09-28
NO331971B1 (no) 2012-05-14
EP1257292B1 (de) 2011-04-27
EA200200890A1 (ru) 2003-02-27
NZ546294A (en) 2008-02-29
EE05423B1 (et) 2011-06-15
KR20020086540A (ko) 2002-11-18
DK1257292T3 (da) 2011-07-18
BR0108514A (pt) 2002-12-17
BG107018A (bg) 2003-09-30
KR20070057282A (ko) 2007-06-04
RS51737B (sr) 2011-10-31
CY1111687T1 (el) 2015-10-07
BG66134B1 (bg) 2011-06-30
JP2003523403A (ja) 2003-08-05
PL357554A1 (en) 2004-07-26
EE200200463A (et) 2003-12-15
HRP20020652A2 (en) 2004-12-31
CZ20022843A3 (cs) 2003-02-12
US20030157094A1 (en) 2003-08-21
TR200502508T2 (tr) 2007-04-24
HUP0300061A2 (hu) 2003-04-28
AU2001240636B8 (en) 2005-11-03
SI1257292T1 (sl) 2011-08-31
AU2001240636B2 (en) 2005-10-13
YU60402A (sh) 2005-09-19
NZ520122A (en) 2005-04-29
CN1404400A (zh) 2003-03-19
SK12082002A3 (sk) 2003-05-02
CA2683009A1 (en) 2001-08-30
HU227752B1 (en) 2012-02-28
PT1257292E (pt) 2011-07-05
EP1257292A1 (de) 2002-11-20
IL151388A0 (en) 2003-04-10
TR200202030T2 (tr) 2003-01-21
AU4063601A (en) 2001-09-03
CN1322897C (zh) 2007-06-27
JP4744763B2 (ja) 2011-08-10
NZ535299A (en) 2006-06-30
CZ304485B6 (cs) 2014-05-28
ME00546B (me) 2011-10-10
SK288032B6 (sk) 2012-12-03
PL206549B1 (pl) 2010-08-31
NO20023962D0 (no) 2002-08-20
CA2683009C (en) 2014-09-23
MXPA02008079A (es) 2003-02-27

Similar Documents

Publication Publication Date Title
ATE506959T1 (de) Verwendung von il-18 inhibitoren
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
GB0223040D0 (en) Therapeutic compounds
GB0025173D0 (en) Therapeutic agents
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
MA27374A1 (fr) Ester de 2'-c-methyl-3'-o-l-valine et de ribofuranosyl cytidine pour le traitement des infections des flaviviridae
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
GB0225474D0 (en) Therapeutic agents
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
ATE232396T1 (de) Oxydiertes thymosin beta 4
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
BRPI0417146A (pt) combinações farmacêuticas
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
FI20000303A0 (fi) Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1257292

Country of ref document: EP